Jazz Pharmaceuticals PLC to Host Investor Webcast to Review Phase 3 Idiopathic Hypersomnia Data Transcript
Good day, and thank you for standing by, and welcome to the Jazz Pharmaceuticals Conference Call and Webcast to Review Xywav Idiopathic Hypersomnia Data Presented at the 2021 American Academy of Neurology Annual Meeting. (Operator Instructions)
I would now like to turn the call over to Dan Swisher, President and Chief Operating Officer. You may begin.
Thanks, Kevin. Welcome, everyone. I'm Dan Swisher, President and Chief Operating Officer at Jazz Pharmaceuticals. Thanks for joining us for today's webcast to discuss the positive results from our Phase III clinical trial of Xywav in idiopathic hypersomnia or IH. On today's call, we will be referencing a slide deck that is available on the Jazz corporate website. You can find the deck in the IR section of the website under Events and Presentations.
So on Slide 2 of this deck, I want to point out that we will be making forward-looking statements during today's presentation. Actual results may differ materially, and the forward
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |